SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-033033
Filing Date
2023-09-26
Accepted
2023-09-26 16:47:09
Documents
15
Period of Report
2023-09-26
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K akba-20230926.htm   iXBRL 8-K 31677
2 EX-99.1 exhibit991-pressrelease.htm EX-99.1 25802
7 GRAPHIC image_0.jpg GRAPHIC 822163
  Complete submission text file 0001628280-23-033033.txt   1324643

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT akba-20230926.xsd EX-101.SCH 2258
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT akba-20230926_def.xml EX-101.DEF 3738
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT akba-20230926_lab.xml EX-101.LAB 27680
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT akba-20230926_pre.xml EX-101.PRE 14595
9 EXTRACTED XBRL INSTANCE DOCUMENT akba-20230926_htm.xml XML 3123
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36352 | Film No.: 231280978
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences